These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 9635530)

  • 1. The extent of proliferative and apoptotic activity in intraductal and invasive ductal breast carcinomas detected by Ki-67 labeling and terminal deoxynucleotidyl transferase-mediated digoxigenin-11-dUTP nick end labeling.
    Shen KL; Harn HJ; Ho LI; Yu CP; Chiu SC; Lee WH
    Cancer; 1998 Jun; 82(12):2373-81. PubMed ID: 9635530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apoptosis occurs more frequently in intraductal carcinoma than in infiltrating duct carcinoma of human breast cancer and correlates with altered p53 expression: detected by terminal-deoxynucleotidyl-transferase-mediated dUTP-FITC nick end labelling (TUNEL).
    Harn HJ; Shen KL; Yueh KC; Ho LI; Yu JC; Chiu SC; Lee WH
    Histopathology; 1997 Dec; 31(6):534-9. PubMed ID: 9447384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
    Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
    Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 mutation in breast cancer. Correlation with cell kinetics and cell of origin.
    Megha T; Ferrari F; Benvenuto A; Bellan C; Lalinga AV; Lazzi S; Bartolommei S; Cevenini G; Leoncini L; Tosi P
    J Clin Pathol; 2002 Jun; 55(6):461-6. PubMed ID: 12037031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extensive apoptosis in ductal carcinoma in situ of the breast.
    Bodis S; Siziopikou KP; Schnitt SJ; Harris JR; Fisher DE
    Cancer; 1996 May; 77(9):1831-5. PubMed ID: 8646681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bax protein expression in DCIS of the breast in relation to invasive ductal carcinoma and other molecular markers.
    Rehman S; Crow J; Revell PA
    Pathol Oncol Res; 2000; 6(4):256-63. PubMed ID: 11173657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alterations of ER, PR, HER-2/neu, and P53 protein expression in ductal breast carcinomas and clinical implications.
    Liu C; Zhang H; Shuang C; Lu Y; Jin F; Xu H; Lu P
    Med Oncol; 2010 Sep; 27(3):747-52. PubMed ID: 19657752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC + DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade.
    Papantoniou V; Sotiropoulou E; Valsamaki P; Tsaroucha A; Sotiropoulou M; Ptohis N; Stipsanelli A; Dimitrakakis K; Marinopoulos S; Tsiouris S; Antsaklis A
    Breast Cancer; 2011 Oct; 18(4):286-91. PubMed ID: 20143189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spontaneous programmed cell death in infiltrating duct carcinoma: association with p53, BCL-2, hormone receptors and tumor proliferation.
    Pillai MR; Kesari AL; Chellam VG; Madhavan J; Nair P; Nair MK
    Pathol Res Pract; 1998; 194(8):549-57. PubMed ID: 9779489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying a highly-aggressive DCIS subgroup by studying intra-individual DCIS heterogeneity among invasive breast cancer patients.
    Pape-Zambito D; Jiang Z; Wu H; Devarajan K; Slater CM; Cai KQ; Patchefsky A; Daly MB; Chen X
    PLoS One; 2014; 9(6):e100488. PubMed ID: 24978026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast carcinogenesis. Transition from hyperplasia to invasive lesions.
    Meteoglu I; Dikicioglu E; Erkus M; Culhaci N; Kacar F; Ozkara E; Uyar M
    Saudi Med J; 2005 Dec; 26(12):1889-96. PubMed ID: 16380768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microsatellite alterations on human chromosome 11 in in situ and invasive breast cancer: a microdissection microsatellite analysis and correlation with p53, ER (estrogen receptor), and PR (progesterone receptor) protein immunoreactivity.
    Shen KL; Yang LS; Hsieh HF; Chen CJ; Yu JC; Tsai NM; Harn HJ
    J Surg Oncol; 2000 Jun; 74(2):100-7. PubMed ID: 10914818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pleomorphic lobular carcinoma of the breast: its cell kinetics, expression of oncogenes and tumour suppressor genes compared with invasive ductal carcinomas and classical infiltrating lobular carcinomas.
    Frolik D; Caduff R; Varga Z
    Histopathology; 2001 Nov; 39(5):503-13. PubMed ID: 11737309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are the pure in situ breast ductal carcinomas and those associated with invasive carcinoma the same?
    Schorr MC; Pedrini JL; Savaris RF; Zettler CG
    Appl Immunohistochem Mol Morphol; 2010 Jan; 18(1):51-4. PubMed ID: 19568168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retinoic acid receptor and retinoid X receptor in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.
    Ariga N; Moriya T; Suzuki T; Kimura M; Ohuchi N; Sasano H
    Jpn J Cancer Res; 2000 Nov; 91(11):1169-76. PubMed ID: 11092983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apoptosis in ductal carcinoma in situ of the breast.
    Moreno A; Figueras A; Lloveras B; Escobedo A; Griera E; Sierra A; Fabra A
    Breast J; 2001; 7(4):245-8. PubMed ID: 11678802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of Bcl-2, but not Bax, correlates with estrogen receptor status and tumor proliferation in invasive breast carcinoma.
    Yang Q; Sakurai T; Jing X; Utsunomiya H; Shan L; Nakamura Y; Nakamura M; Oura S; Suzuma T; Yoshimura G; Umemura T; Kokawa Y; Kakudo K
    Pathol Int; 1999 Sep; 49(9):775-80. PubMed ID: 10504548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bcl-2 expression and DNA fragmentation in breast carcinoma, pathologic and steroid hormone receptors correlates.
    Diaz-Cano SJ; Garcia-Moliner M; Carney W; Wolfe HJ
    Diagn Mol Pathol; 1997 Aug; 6(4):199-208. PubMed ID: 9360841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial.
    Bundred NJ; Cramer A; Morris J; Renshaw L; Cheung KL; Flint P; Johnson R; Young O; Landberg G; Grassby S; Turner L; Baildam A; Barr L; Dixon JM
    Clin Cancer Res; 2010 Mar; 16(5):1605-12. PubMed ID: 20179229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer.
    Wong H; Lau S; Yau T; Cheung P; Epstein RJ
    Br J Cancer; 2010 Apr; 102(9):1391-6. PubMed ID: 20424617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.